Cingulate (NASDAQ:CING) Stock Dropped to “Strong Sell” by Wall Street Zen

Cingulate (NASDAQ:CING – Get Free Report) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday, Wall Street Zen reports.

A number of other research analysts also recently issued reports on CING. Roth Capital set a $9.00 price objective on Cingulate and gave the company a “buy” rating in a research note on Sunday, August 23rd. Weiss Ratings cut Cingulate from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 3rd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Cingulate currently has an average rating of “Moderate Buy” and a consensus price target of $27.00.

View Our Latest Report on Cingulate

Cingulate Trading Down 14.3%

Cingulate stock opened at $4.51 on Friday. The stock has a 50-day moving average price of $4.81 and a two-hundred day moving average price of $5.36. Cingulate has a 12 month low of $3.16 and a 12 month high of $11.89.

Cingulate (NASDAQ:CING – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.10). As a group, equities analysts predict that Cingulate will post -2.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cingulate

Hedge funds have recently made changes to their positions in the business. Kestra Advisory Services LLC boosted its holdings in shares of Cingulate by 14.8% in the 1st quarter. Kestra Advisory Services LLC now owns 140,000 shares of the company’s stock worth $869,000 after buying an additional 18,000 shares during the last quarter. BlackRock Inc. bought a new position in Cingulate during the second quarter valued at about $291,000. Finally, Renaissance Technologies LLC purchased a new stake in Cingulate during the first quarter worth about $198,000. 41.31% of the stock is currently owned by institutional investors.

Cingulate Company Profile

(Get Free Report)

Cingulate is a clinical-stage biopharmaceutical company developing prescription treatments for attention-deficit/hyperactivity disorder (ADHD). The company’s approach is to improve how existing medicines are delivered over the course of the day. Its lead candidate, CTx-1301, is an extended-release formulation of dexmethylphenidate designed to provide multiple timed releases of medication. Cingulate is also developing CTx-1302, another candidate for ADHD. The company uses its proprietary Precision Timed Release drug-delivery platform to develop these candidates.

Featured Articles

Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.